Drug Trial Radar · NCT06973005
A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
May 8, 2025
Primary completion
Jul 18, 2025
Study completion Jul 18, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- May 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the effect of multiple doses of AZD2389 on the pharmacokinetics (PK) of midazolam, caffeine, and bupropion in healthy participants.
Conditions
- Advanced Chronic Liver Disease
- Healthy Participants
Interventions
AZD2389Drug
Oral dose on Days 5 to 13, Day 16, and Day 17. On Day 14 co-administered with a combination of midazolam and caffeine. On Day 15 co-administered with bupropion.
MidazolamDrug
Single oral dose on: * Day 1 (co-administered with caffeine) * Day 14 (co-administered with caffeine and AZD2389)
CaffeineDrug
Single oral dose on: * Day 1 (co-administered with midazolam) * Day 14 (co-administered with midazolam and AZD2389)
BupropionDrug
Single oral dose on: * Day 2 (alone) * Day 15 (co-administered with AZD2389)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of treatment to reference based on Cmax (RCmax)Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
- Ratio of treatment to reference based on AUCinf (RAUCinf)Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
- Ratio of treatment to reference based on AUClast (RAUClast)Time frame: Period 1: Days 1-4; Period 2: Days 5-13; Period 3: Days 14-18.
- Ratio of area under concentration-curve from time 0 to 24 hours post-dose (AUC0-24)Time frame: Period 1: Days 1-3; Period 3: Days 15-18.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Brooklyn, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.